The California State Legislature passed the California Cancer Care Equity Act (SB 987), a bill that would expand access to specialized cancer care for Medi-Cal patients who receive a complex cancer diagnosis.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
